Advanced Implantable and Non-Invasive Stimulators for Enhanced Gastrointestinal Therapeutics

This inventive concept discloses advanced implantable and non-invasive stimulators that provide real-time feedback, personalized stimulation therapy, and improved gastrointestinal motility regulation, thereby enhancing the treatment of gastrointestinal dysmotility and related disorders.

The original patent, 'Implantable and non-invasive stimulators for gastrointestinal therapeutics', provides a foundation for gastrointestinal stimulation. However, it has limitations in terms of providing real-time feedback, personalization, and precise control over stimulation parameters. The new inventive concept addresses these limitations by integrating advanced sensors, miniaturized implants, and user interfaces to provide more effective and efficient gastrointestinal stimulation.

The advanced stimulators comprise miniaturized implants with integrated power sources and sensors for detecting gastrointestinal motility. These implants provide real-time feedback to users, enabling optimization of stimulation parameters. Non-invasive transcutaneous stimulators are also integrated with wearable sensors to detect gastrointestinal motility, providing personalized stimulation therapy. The system can be controlled by user interfaces, such as mobile devices, to receive input from users and adjust stimulation accordingly. Additionally, the stimulators can be disposable and rechargeable, reducing the need for frequent replacements.

The new claims introduce the concept of real-time feedback, personalized stimulation therapy, and improved gastrointestinal motility regulation, which are not present in the original patent. The integration of advanced sensors, miniaturized implants, and user interfaces provides a novel and non-obvious solution to the limitations of the original patent.

Alternative embodiments may include the use of different types of sensors, such as impedance sensors or pH sensors, to detect gastrointestinal motility. Variations may also include the integration of artificial intelligence algorithms to optimize stimulation parameters based on user feedback and physiological signals.

The advanced implantable and non-invasive stimulators have significant commercial potential in the treatment of gastrointestinal dysmotility and related disorders, such as irritable bowel syndrome, gastroparesis, and inflammatory bowel disease. The target market includes medical device companies, hospitals, and healthcare providers specializing in gastrointestinal care.